New Launch3 Mar 2026, 10:34 am
Natco Pharma Launches Generic Version of Pomalyst® in U.S. Market with Estimated Sales of USD 3.2 Billion
AI Summary
Natco Pharma Limited, in partnership with Breckenridge Pharmaceutical, Inc, has announced the launch of Pomalidomide Capsules, a generic version of Pomalyst® by Celgene, in the U.S. market. The product, available in 1mg, 2mg, 3mg, and 4mg strengths, is indicated for the treatment of multiple myeloma and Kaposi sarcoma. It had estimated sales of USD 3.2 billion in the U.S. for 12 months ending Sep’25. Natco believes it has 180 days of shared exclusivity. The launch strengthens Natco’s oncology and specialty portfolio in the U.S. and underscores Breckenridge’s commitment to expanding its specialty generics portfolio.
Key Highlights
- Natco Pharma and Breckenridge Pharmaceutical announce launch of Pomalidomide Capsules, a generic version of Pomalyst®, in the U.S. market.
- Pomalidomide Capsules are indicated for the treatment of multiple myeloma and Kaposi sarcoma.
- The product is available in 1mg, 2mg, 3mg, and 4mg strengths and had estimated sales of USD 3.2 billion in the U.S. for 12 months ending Sep’25.
- Natco believes it has 180 days of shared exclusivity.
- Launch strengthens Natco’s oncology and specialty portfolio in the U.S. and underscores Breckenridge’s commitment to expanding its specialty generics portfolio.